Compare KALA & XXII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KALA | XXII |
|---|---|---|
| Founded | 2009 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7M | 6.1M |
| IPO Year | 2017 | N/A |
| Metric | KALA | XXII |
|---|---|---|
| Price | $0.56 | $0.77 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $31.50 | N/A |
| AVG Volume (30 Days) | ★ 20.4M | 160.7K |
| Earning Date | 11-19-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $20,346,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $79.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 16.98 |
| 52 Week Low | $0.51 | $0.78 |
| 52 Week High | $20.60 | $287.27 |
| Indicator | KALA | XXII |
|---|---|---|
| Relative Strength Index (RSI) | 37.14 | 31.29 |
| Support Level | $0.57 | $0.90 |
| Resistance Level | $0.72 | $0.88 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 20.52 | 2.55 |
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.